GENE ONLINE|News &
Opinion
Blog

2026-04-02|

Dr. Thales Papagiannakopoulos to Join Salk Institute Faculty in September 2026 for Cancer Research Expansion

by GOAI
Share To

The Salk Institute has announced the upcoming addition of Dr. Thales “PapaG” Papagiannakopoulos to its faculty, marking a significant development in its cancer research efforts. Dr. Papagiannakopoulos, an expert in cancer metabolism, immunology, and tumor-host communication, will join the institute as a professor starting in September 2026. He currently serves at NYU Grossman School of Medicine and is recognized for his contributions to understanding the complex interactions between tumors and their surrounding environments.

Dr. Papagiannakopoulos’s work focuses on how metabolic processes influence cancer progression and how tumors interact with immune systems and host tissues. His appointment is expected to bolster the Salk Institute’s ongoing research into innovative approaches for combating cancer. The institute has described this recruitment as part of its broader commitment to advancing scientific knowledge in oncology through collaboration with leading experts in the field.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 2, 2026

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
LATEST
[Illustrations] The Diversity Deficit in Oncology Trials: When Enrollment Logic No Longer Reflects Real-World Patients
2026-04-16
Japanese Researchers Identify Stem Cell Dynamics in Vocal Fold Tissue Maintenance and Repair
2026-04-16
Study Identifies Active Role of Skin Cells in Rabies Virus Replication and Transmission
2026-04-16
Contractor Fatality Halts Operations at ATEX Resources’ Valeriano Project in Chile
2026-04-15
Dual Inhibition of xCT and GGCT Induces Ferroptosis in Glioblastoma Cells
2026-04-15
Researchers Develop Method to Convert Ketones into Saturated Heterocycles for Pharmaceutical Applications
2026-04-15
Naturally Occurring Compounds Luteolin, Naringenin, and Scutellarin Identified as Potential Inhibitors of Breast Cancer-Linked Enzymes HDAC4 and HDAC8
2026-04-15
Scroll to Top